Immunic, Inc. 8-K Report: Key Insights from December 13, 2024 Filing
Here are the key pieces of information extracted from the provided financial report section:
- Entity Information:
- Name: Immunic, Inc.
- CIK: 0001280776
- State of Incorporation: Delaware (DE)
- SEC File Number: 001-36201
- EIN: 56-2358443
- Address: 1200 Avenue of the Americas, Suite 200, New York, NY 10036, US
- Contact Number: (332) 255-9818
- Trading Symbol: IMUX
- Report Details:
- Filing Type: 8-K
- Filing Date: December 13, 2024
- Financial Metrics:
- Common Stock: Par value of $0.0001
- Unit of Measure:
- Currency: USD (United States Dollar)
- Shares: Measured in shares
- Context Information:
- Period Covered: The report pertains to a single day, December 13, 2024.
- Regulatory References:
- The report is structured using XBRL (eXtensible Business Reporting Language), which is a standard for digital financial reporting.
Insights:
- The report is a current event filing (8-K), which typically indicates that significant corporate events or changes have occurred that warrant immediate disclosure to investors.
- The provided information confirms that Immunic, Inc. is a publicly traded company listed on NASDAQ, suggesting it falls under the regulatory scrutiny of the SEC and must comply with financial reporting and transparency obligations.
- The focus on common stock and par value indicates potential discussions around equity financing or shareholder equity levels that could be relevant for investors and analysts following the company's performance.
This information serves as a foundation for further analysis of Immunic, Inc.'s financial health and strategic initiatives.